Annual evolution of the prescription of drugs with prognostic implications in acute decompensated heart failure with reduced ejection fraction

Annual evolution of the prescription of drugs with prognostic implications in acute decompensated heart failure with reduced ejection fraction

Abstract Background Quadruple therapy (renin angiotensin system inhibitors, beta-blockers, mineralocorticoid receptor antagonists and sodium/glucose cotransporter type 2 inhibitors [SGLT2i]) has become the current prognostic modifying treatment for heart failure (HF) with reduced ejection fraction (...

Full description

Bibliographic Details
Main Authors: Raquel López-Vilella, Víctor DonosoTrenado, Borja Guerrero Cervera, Ignacio Sánchez-Lázaro, Luis Martínez Dolz, Luis Almenar Bonet
Format: Article
Language:English
Published: BMC 2024-02-01
Series:BMC Cardiovascular Disorders
Subjects:
Quadruple therapy
Acute heart failure
Heart failure subgroups
Prescription
Evolution
Online Access:https://doi.org/10.1186/s12872-024-03728-y

Internet

https://doi.org/10.1186/s12872-024-03728-y

Similar Items